A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant

Leukemia

Volumn 18, Issue 10, 2004, Pages 1717-1721

  Laporte, Jean Philippe ^a   Yeshurun, M ^a,b,c   Fouillard, L ^a   Labopin, M ^a   Cailliot, C ^a,d   Lesage, S ^a   Isnard, F ^a   Najman, A ^a   Gorin, N C ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b Chaim Medical Centre   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d AMGEN   (France)

Author keywords

Erythropoietin; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Non Hodgkin's lymphoma; Transplantation conditioning

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; CYTOKINE; ETOPOSIDE; HEMOGLOBIN; MELPHALAN; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INFILTRATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; INTERSTITIAL PNEUMONIA; MALE; MINIMAL RESIDUAL DISEASE; MYCOSIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT FAILURE; VIRUS INFECTION;

EID: 6344262370     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403427     Document Type: Article

References (26)

1. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH-87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
2. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemosensitive-chemotherapy non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
4. Fouillard L, Laporte JPh, Labopin M, Lesage S, Isnard F, Douay L et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation - results of a retrospective analysis of 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803-2816.
5. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527-536.
6. Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M et al. Value of autologous stem cell transplantation with purged bone marrow a first-line therapy for follicular lymphoma with high tumour burden: a GOELAMS phase 11 study. Bone Marrow Transplant 2000; 26: 971-977.
7. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC et al. High-dose chemotherapy and autologous stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
8. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454-2464.
9. Gribben JG, Neuberg D, Freedman AS, Roy DC, Blake KW, Woo SD et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
10. Freedman AS, Friedberg J, Gribben JG. High dose therapy for follicular lymphoma. Oncology 2000; 329: 321-326.
11. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
12. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
14. Fouillard L, Gorin N, Laporte JPh, Douay L, Isnard F, Najman A. Recombinant human granulocyte macrophage colony stimulating factor+the BEAM regimen instead of autologous bone marrow transplantation. Lancet 1989; 1: 1460.
15. Laporte JPh, Fouillard L, Douay L, Eugene-Jolchine I, Isnard F, Stachowiak J et al. GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen. Lancet 1991; 338: 601-602.
16. Douay L. Experimental culture conditions are critical for ex vivo expansion of hematopoietic cells: review. J Haematother Stem Cell Res 2001, 341-346.
17. Pierelli L, Menichella G, Scambia G, Teofili L, Iovino S, Serafini R et al. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 1994; 14 23-30.
18. Filip S, Vanasek J, Blaha M, Mericka P, Vavrova J, Podzimek K. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte-stimulating factor (G-CSF) with peripheral blood progenitor cells after intensive cyclic chemotherapy in high risk breast cancer patients. Neoplasma 1999; 46: 166.
19. Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous vs allogeneic transplantation. Bone Marrow Transplant 1994; 13: 403-410.
20. Locatelli F, Zecca M, Ponchio L, Beguin Y, Giorgiani G, Maccario R et al. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 23-30.
21. Laporte JPh, Lesage S, Woler M, Parlier Y, Daguenel A, Najman A et al. Administration of three cytokines instead of bone marrow tranplantation in a HIV+ patient with high-grade lymphoma. Eur J Haematol 1994, 123-125.
22. Tothova E, Kafkova A, Guman T, Stecova N, Fricova M. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. Neoplasma 2003; 50: 22-25.
23. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S et al. Increased incidence of CMV disease after autologous CD34 selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029.
24. Fouillard L, Laporte JPh, Douay L, Lesage S, Najman A, Gourmelon P et al. In vivo expansion of reinfused autologous peripheral blood stem cells after a myeloablative regimen, as an alternative to ex vivo expansion pretransplantation: an intriguing observation in a patient autografted twice. Bone Marrow Transplant 1999; 24: 1151-1152.
25. Blaise D, Faucher C, Vey N, Caraux J, Maraninchi D, Chabannon C. Rescue of hemopoiesis by a combination of growth factors including stem-cell factor. Lancet 2000; 14: 1325-1326.
26. Bomberger C, Singh-Jairam M, Rodey G, Guerriero A, Yeager AM, Fleming WH et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998; 91: 2588-2600.